BRIEF published on 12/11/2025 at 23:05, 6 months 21 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 6 months 21 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 7 months 12 days ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 7 months 12 days ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 7 months 18 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 7 months 18 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 8 months 22 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE published on 10/10/2025 at 15:30, 8 months 22 days ago Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF published on 08/13/2025 at 14:05, 10 months 19 days ago Xenetic Biosciences Reports Q2 2025 Financial Results Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE published on 08/13/2025 at 14:00, 10 months 19 days ago Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
Published on 07/02/2026 at 13:05, 10 minutes ago Faraday Copper Signs a Definitive Agreement to Acquire BHP's San Manuel Property in Arizona, Creating a Multi-Asset Copper District in the USA
Published on 07/02/2026 at 13:00, 15 minutes ago Aztec Engages Kappes, Cassiday & Associates to Advance Metallurgical Testing of Oxide Gold-Silver Mineralization at Tombstone
Published on 07/02/2026 at 12:35, 40 minutes ago EQS-Adhoc: Circus Completes Acquisition of Belgian Food Robotics Company Alberts
Published on 07/02/2026 at 11:05, 2 hours 9 minutes ago Daniel Hilkert Takes on Additional Role as Chief Product Officer at zvoove Group
Published on 07/02/2026 at 11:00, 2 hours 15 minutes ago EQS Group expands Privacy Cockpit with AI governance capabilities for EU AI Act readiness
Published on 07/01/2026 at 18:26, 18 hours 49 minutes ago Modula renews its confidence in AMA with a four-year agreement integrating XpertEye’s new AI-powered features
Published on 07/01/2026 at 17:54, 19 hours 20 minutes ago TF1 - Monthly disclosure of the total number of shares and voting rights - June 2026
Published on 07/01/2026 at 17:45, 19 hours 30 minutes ago Availability of the Pre-H1 2026 Results Communication
Published on 07/01/2026 at 17:40, 19 hours 35 minutes ago Report on share repurchases from 24 to 30 June 2026
Published on 07/01/2026 at 17:35, 19 hours 40 minutes ago Disclosure of transactions in own shares from June 29 to June 30, 2026
